Pyrrolidine → HCID 178515202, compound
Reaction equation
[C:1]1([N:7]2[C:25](=[O:26])[C:10]3=[CH:11][NH:12][C:13]4[CH:14]=[CH:15][C:16]([N:19]5[CH2:24][CH2:23]N[CH2:21][CH2:20]5)=[N:17][C:18]=4[C:9]3=[N:8]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.N1CCCC1>>[C:1]1([N:7]2[C:25](=[O:26])[C:10]3=[CH:11][NH:12][C:13]4[CH:14]=[CH:15][C:16]([N:19]5[CH2:24][CH2:23][CH2:21][CH2:20]5)=[N:17][C:18]=4[C:9]3=[N:8]2)[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=1Participants
3
Procedure
The title compound was prepared following the procedure described for 6a using pyrrolidine instead of piperazine. 1H-NMR (DMSO-d6) δ (ppm): 1.99 (4H, br), 3.49 (4H, br), 6.77 (1H, d, J=9.06 Hz), 7.05 (1H, tt, J=7.41, 0.89 Hz), 7.37 (2H, m), 7.77 (1H, d, J=9.07 Hz), 8.28 (2H, dd, J=7.70, 1.09 Hz), 8.34 (1H, s). m/z 332.4 (MH+).
Sources & evidence
- ORD record
- ord-d97cd104823c449688e4bc3aa98573ae
- Source dataset
- uspto-grants-2010_12
- Patent number
- US07858614B2
Reaction notes
Loading…